Viral Clearance Service
Viral Clearance Service

Viral Clearance Service Comprehensive Study by Application (Recombinant Proteins, Blood and Blood Products, Vaccines, Other), End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, Others), Method Type (Viral Removal, Chromatography, Nanofiltration, Precipitation, Viral Inactivation, Others) Players and Region - Global Market Outlook to 2026

Viral Clearance Service Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 245 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Viral Clearance is critical in the process development for monoclonal antibodies, recombinant proteins, and glycoproteins, tissue and blood-derived products, and medical devices. In the creation of monoclonal antibodies, recombinant proteins and glycoproteins, tissue and blood-derived products, and medical devices, viral clearance is critical. This is due to the potential of germs and fungi, as well as chemical contaminants and viruses, contaminating these items. This has an impact on the market for viral safety practices as well as the integration of virus clearance processes into the development chain. Bacteria, fungi, and viruses can attack biological products. Pollution is caused by raw materials and inappropriate cultural treatment.The global viral clearance industry is being driven by increased demand in the pharmaceutical and biotechnology industries. Furthermore, the market is being propelled by an increase in the number of new drug releases in various categories, as well as related drug approval procedures. Furthermore, the number of new pharmaceuticals is expanding, as are government policies. Quality assurance and quality management departments, on the other hand, play a significant role in the worldwide virus clearance industry's growth.This growth is primarily driven by Growth in the Pharmaceutical and Biotechnology Industries and Increasing Number of Drug Launches.

Globally, a noticeable market trend is evident Development of Nanofiltration Technology. Major Players, such as Wuxi Biologics (China), Sartorius AG (Germany), Eurofins Scientific (Luxembourg), Merck KGaA (Germany), BioScience Laboratories (United States), Charles River Laboratories International Inc. (United States), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany) and ViruSure GmbH (Austria) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
September 2020 Merck, a leading science and technology company, has announced an expansion of its Singapore biosafety testing laboratory services. These services allow customers to conduct viral clearance studies that ensure the safety and quality of their biological drugs during the clinical development process.

Market Drivers
  • Growth in the Pharmaceutical and Biotechnology Industries
  • Increasing Number of Drug Launches

Market Trend
  • Development of Nanofiltration Technology

Restraints
  • Cost and Time-Intensive Drug Development Process

Opportunities
Rise in Research and Development Activities and Increasing Pharmaceutical Outsourcing
Challenges
Rise in Research and Development Activities

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Viral Clearance Service Study Sheds Light on
— The Viral Clearance Service Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Viral Clearance Service industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Viral Clearance Service industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the Viral Clearance Service Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026

2. Who are the key players profiled in the Viral Clearance Service Market?
Companies that are profiled in Global Viral Clearance Service Market are Wuxi Biologics (China), Sartorius AG (Germany), Eurofins Scientific (Luxembourg), Merck KGaA (Germany), BioScience Laboratories (United States), Charles River Laboratories International Inc. (United States), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany) and ViruSure GmbH (Austria) etc.

3. What is Viral Clearance Service Market?
Viral Clearance is critical in the process development for monoclonal antibodies, recombinant proteins, and glycoproteins, tissue and blood-derived products, and medical devices. In the creation of monoclonal antibodies, recombinant proteins and glycoproteins, tissue and blood-derived products, and medical devices, viral clearance is critical. This is due to the potential of germs and fungi, as well as chemical contaminants and viruses, contaminating these items. This has an impact on the market for viral safety practices as well as the integration of virus clearance processes into the development chain. Bacteria, fungi, and viruses can attack biological products. Pollution is caused by raw materials and inappropriate cultural treatment.The global viral clearance industry is being driven by increased demand in the pharmaceutical and biotechnology industries. Furthermore, the market is being propelled by an increase in the number of new drug releases in various categories, as well as related drug approval procedures. Furthermore, the number of new pharmaceuticals is expanding, as are government policies. Quality assurance and quality management departments, on the other hand, play a significant role in the worldwide virus clearance industry's growth.
Report Objectives / Segmentation Covered
By Application
  • Recombinant Proteins
  • Blood and Blood Products
  • Vaccines
  • Other
By End-User
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academic Research Institutes
  • Others

By Method Type
  • Viral Removal
  • Chromatography
  • Nanofiltration
  • Precipitation
  • Viral Inactivation
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growth in the Pharmaceutical and Biotechnology Industries
      • 3.2.2. Increasing Number of Drug Launches
    • 3.3. Market Challenges
      • 3.3.1. Rise in Research and Development Activities
    • 3.4. Market Trends
      • 3.4.1. Development of Nanofiltration Technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Viral Clearance Service, by Application, End-User, Method Type and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Viral Clearance Service (Value)
      • 5.2.1. Global Viral Clearance Service by: Application (Value)
        • 5.2.1.1. Recombinant Proteins
        • 5.2.1.2. Blood and Blood Products
        • 5.2.1.3. Vaccines
        • 5.2.1.4. Other
      • 5.2.2. Global Viral Clearance Service by: End-User (Value)
        • 5.2.2.1. Pharmaceutical & Biotechnology Companies
        • 5.2.2.2. Contract Research Organizations
        • 5.2.2.3. Academic Research Institutes
        • 5.2.2.4. Others
      • 5.2.3. Global Viral Clearance Service by: Method Type (Value)
        • 5.2.3.1. Viral Removal
        • 5.2.3.2. Chromatography
        • 5.2.3.3. Nanofiltration
        • 5.2.3.4. Precipitation
        • 5.2.3.5. Viral Inactivation
        • 5.2.3.6. Others
      • 5.2.4. Global Viral Clearance Service Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Viral Clearance Service: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Wuxi Biologics (China)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sartorius AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eurofins Scientific (Luxembourg)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck KGaA (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BioScience Laboratories (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Charles River Laboratories International Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Vironova Biosafety (Sweden)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Clean Cells (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. ViruSure GmbH (Austria)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Viral Clearance Service Sale, by Application, End-User, Method Type and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Viral Clearance Service (Value)
      • 7.2.1. Global Viral Clearance Service by: Application (Value)
        • 7.2.1.1. Recombinant Proteins
        • 7.2.1.2. Blood and Blood Products
        • 7.2.1.3. Vaccines
        • 7.2.1.4. Other
      • 7.2.2. Global Viral Clearance Service by: End-User (Value)
        • 7.2.2.1. Pharmaceutical & Biotechnology Companies
        • 7.2.2.2. Contract Research Organizations
        • 7.2.2.3. Academic Research Institutes
        • 7.2.2.4. Others
      • 7.2.3. Global Viral Clearance Service by: Method Type (Value)
        • 7.2.3.1. Viral Removal
        • 7.2.3.2. Chromatography
        • 7.2.3.3. Nanofiltration
        • 7.2.3.4. Precipitation
        • 7.2.3.5. Viral Inactivation
        • 7.2.3.6. Others
      • 7.2.4. Global Viral Clearance Service Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Viral Clearance Service: by Application(USD Million)
  • Table 2. Viral Clearance Service Recombinant Proteins , by Region USD Million (2015-2020)
  • Table 3. Viral Clearance Service Blood and Blood Products , by Region USD Million (2015-2020)
  • Table 4. Viral Clearance Service Vaccines , by Region USD Million (2015-2020)
  • Table 5. Viral Clearance Service Other , by Region USD Million (2015-2020)
  • Table 6. Viral Clearance Service: by End-User(USD Million)
  • Table 7. Viral Clearance Service Pharmaceutical & Biotechnology Companies , by Region USD Million (2015-2020)
  • Table 8. Viral Clearance Service Contract Research Organizations , by Region USD Million (2015-2020)
  • Table 9. Viral Clearance Service Academic Research Institutes , by Region USD Million (2015-2020)
  • Table 10. Viral Clearance Service Others , by Region USD Million (2015-2020)
  • Table 11. Viral Clearance Service: by Method Type(USD Million)
  • Table 12. Viral Clearance Service Viral Removal , by Region USD Million (2015-2020)
  • Table 13. Viral Clearance Service Chromatography , by Region USD Million (2015-2020)
  • Table 14. Viral Clearance Service Nanofiltration , by Region USD Million (2015-2020)
  • Table 15. Viral Clearance Service Precipitation , by Region USD Million (2015-2020)
  • Table 16. Viral Clearance Service Viral Inactivation , by Region USD Million (2015-2020)
  • Table 17. Viral Clearance Service Others , by Region USD Million (2015-2020)
  • Table 18. South America Viral Clearance Service, by Country USD Million (2015-2020)
  • Table 19. South America Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 20. South America Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 21. South America Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 22. Brazil Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 23. Brazil Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 24. Brazil Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 25. Argentina Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 26. Argentina Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 27. Argentina Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 28. Rest of South America Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 30. Rest of South America Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 31. Asia Pacific Viral Clearance Service, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 34. Asia Pacific Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 35. China Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 36. China Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 37. China Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 38. Japan Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 39. Japan Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 40. Japan Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 41. India Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 42. India Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 43. India Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 44. South Korea Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 45. South Korea Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 46. South Korea Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 47. Taiwan Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 48. Taiwan Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 49. Taiwan Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 50. Australia Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 51. Australia Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 52. Australia Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 56. Europe Viral Clearance Service, by Country USD Million (2015-2020)
  • Table 57. Europe Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 58. Europe Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 59. Europe Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 60. Germany Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 61. Germany Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 62. Germany Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 63. France Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 64. France Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 65. France Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 66. Italy Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 67. Italy Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 68. Italy Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 69. United Kingdom Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 70. United Kingdom Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 71. United Kingdom Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 72. Netherlands Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 73. Netherlands Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 74. Netherlands Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 75. Rest of Europe Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 76. Rest of Europe Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 77. Rest of Europe Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 78. MEA Viral Clearance Service, by Country USD Million (2015-2020)
  • Table 79. MEA Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 80. MEA Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 81. MEA Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 82. Middle East Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 83. Middle East Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 84. Middle East Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 85. Africa Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 86. Africa Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 87. Africa Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 88. North America Viral Clearance Service, by Country USD Million (2015-2020)
  • Table 89. North America Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 90. North America Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 91. North America Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 92. United States Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 93. United States Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 94. United States Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 95. Canada Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 96. Canada Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 97. Canada Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 98. Mexico Viral Clearance Service, by Application USD Million (2015-2020)
  • Table 99. Mexico Viral Clearance Service, by End-User USD Million (2015-2020)
  • Table 100. Mexico Viral Clearance Service, by Method Type USD Million (2015-2020)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Viral Clearance Service: by Application(USD Million)
  • Table 112. Viral Clearance Service Recombinant Proteins , by Region USD Million (2021-2026)
  • Table 113. Viral Clearance Service Blood and Blood Products , by Region USD Million (2021-2026)
  • Table 114. Viral Clearance Service Vaccines , by Region USD Million (2021-2026)
  • Table 115. Viral Clearance Service Other , by Region USD Million (2021-2026)
  • Table 116. Viral Clearance Service: by End-User(USD Million)
  • Table 117. Viral Clearance Service Pharmaceutical & Biotechnology Companies , by Region USD Million (2021-2026)
  • Table 118. Viral Clearance Service Contract Research Organizations , by Region USD Million (2021-2026)
  • Table 119. Viral Clearance Service Academic Research Institutes , by Region USD Million (2021-2026)
  • Table 120. Viral Clearance Service Others , by Region USD Million (2021-2026)
  • Table 121. Viral Clearance Service: by Method Type(USD Million)
  • Table 122. Viral Clearance Service Viral Removal , by Region USD Million (2021-2026)
  • Table 123. Viral Clearance Service Chromatography , by Region USD Million (2021-2026)
  • Table 124. Viral Clearance Service Nanofiltration , by Region USD Million (2021-2026)
  • Table 125. Viral Clearance Service Precipitation , by Region USD Million (2021-2026)
  • Table 126. Viral Clearance Service Viral Inactivation , by Region USD Million (2021-2026)
  • Table 127. Viral Clearance Service Others , by Region USD Million (2021-2026)
  • Table 128. South America Viral Clearance Service, by Country USD Million (2021-2026)
  • Table 129. South America Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 130. South America Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 131. South America Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 132. Brazil Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 133. Brazil Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 134. Brazil Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 135. Argentina Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 136. Argentina Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 137. Argentina Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 138. Rest of South America Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 139. Rest of South America Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 140. Rest of South America Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 141. Asia Pacific Viral Clearance Service, by Country USD Million (2021-2026)
  • Table 142. Asia Pacific Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 143. Asia Pacific Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 144. Asia Pacific Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 145. China Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 146. China Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 147. China Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 148. Japan Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 149. Japan Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 150. Japan Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 151. India Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 152. India Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 153. India Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 154. South Korea Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 155. South Korea Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 156. South Korea Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 157. Taiwan Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 158. Taiwan Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 159. Taiwan Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 160. Australia Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 161. Australia Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 162. Australia Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 166. Europe Viral Clearance Service, by Country USD Million (2021-2026)
  • Table 167. Europe Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 168. Europe Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 169. Europe Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 170. Germany Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 171. Germany Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 172. Germany Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 173. France Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 174. France Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 175. France Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 176. Italy Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 177. Italy Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 178. Italy Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 179. United Kingdom Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 180. United Kingdom Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 181. United Kingdom Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 182. Netherlands Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 183. Netherlands Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 184. Netherlands Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 185. Rest of Europe Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 186. Rest of Europe Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 187. Rest of Europe Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 188. MEA Viral Clearance Service, by Country USD Million (2021-2026)
  • Table 189. MEA Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 190. MEA Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 191. MEA Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 192. Middle East Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 193. Middle East Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 194. Middle East Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 195. Africa Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 196. Africa Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 197. Africa Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 198. North America Viral Clearance Service, by Country USD Million (2021-2026)
  • Table 199. North America Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 200. North America Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 201. North America Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 202. United States Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 203. United States Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 204. United States Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 205. Canada Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 206. Canada Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 207. Canada Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 208. Mexico Viral Clearance Service, by Application USD Million (2021-2026)
  • Table 209. Mexico Viral Clearance Service, by End-User USD Million (2021-2026)
  • Table 210. Mexico Viral Clearance Service, by Method Type USD Million (2021-2026)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Viral Clearance Service: by Application USD Million (2015-2020)
  • Figure 5. Global Viral Clearance Service: by End-User USD Million (2015-2020)
  • Figure 6. Global Viral Clearance Service: by Method Type USD Million (2015-2020)
  • Figure 7. South America Viral Clearance Service Share (%), by Country
  • Figure 8. Asia Pacific Viral Clearance Service Share (%), by Country
  • Figure 9. Europe Viral Clearance Service Share (%), by Country
  • Figure 10. MEA Viral Clearance Service Share (%), by Country
  • Figure 11. North America Viral Clearance Service Share (%), by Country
  • Figure 12. Global Viral Clearance Service share by Players 2020 (%)
  • Figure 13. Global Viral Clearance Service share by Players (Top 3) 2020(%)
  • Figure 14. Global Viral Clearance Service share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Wuxi Biologics (China) Revenue, Net Income and Gross profit
  • Figure 17. Wuxi Biologics (China) Revenue: by Geography 2020
  • Figure 18. Sartorius AG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Sartorius AG (Germany) Revenue: by Geography 2020
  • Figure 20. Eurofins Scientific (Luxembourg) Revenue, Net Income and Gross profit
  • Figure 21. Eurofins Scientific (Luxembourg) Revenue: by Geography 2020
  • Figure 22. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 24. BioScience Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 25. BioScience Laboratories (United States) Revenue: by Geography 2020
  • Figure 26. Charles River Laboratories International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Charles River Laboratories International Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Vironova Biosafety (Sweden) Revenue, Net Income and Gross profit
  • Figure 29. Vironova Biosafety (Sweden) Revenue: by Geography 2020
  • Figure 30. Clean Cells (France) Revenue, Net Income and Gross profit
  • Figure 31. Clean Cells (France) Revenue: by Geography 2020
  • Figure 32. BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 33. BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany) Revenue: by Geography 2020
  • Figure 34. ViruSure GmbH (Austria) Revenue, Net Income and Gross profit
  • Figure 35. ViruSure GmbH (Austria) Revenue: by Geography 2020
  • Figure 36. Global Viral Clearance Service: by Application USD Million (2021-2026)
  • Figure 37. Global Viral Clearance Service: by End-User USD Million (2021-2026)
  • Figure 38. Global Viral Clearance Service: by Method Type USD Million (2021-2026)
  • Figure 39. South America Viral Clearance Service Share (%), by Country
  • Figure 40. Asia Pacific Viral Clearance Service Share (%), by Country
  • Figure 41. Europe Viral Clearance Service Share (%), by Country
  • Figure 42. MEA Viral Clearance Service Share (%), by Country
  • Figure 43. North America Viral Clearance Service Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Wuxi Biologics (China)
  • Sartorius AG (Germany)
  • Eurofins Scientific (Luxembourg)
  • Merck KGaA (Germany)
  • BioScience Laboratories (United States)
  • Charles River Laboratories International Inc. (United States)
  • Vironova Biosafety (Sweden)
  • Clean Cells (France)
  • BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany)
  • ViruSure GmbH (Austria)
Additional players considered in the study are as follows:
Texcell Inc. (France) , Kedrion (Italy)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation